Agonists
at the α2 adrenergic receptor produce
sedation, increase focus, provide analgesia, and induce centrally
mediated hypotension and bradycardia, yet neither their dynamic interactions
with adrenergic receptors nor their modulation of neuronal circuit
activity is completely understood. Photoaffinity ligands of α2 adrenergic agonists have the potential both to capture discrete
moments of ligand–receptor interactions and to prolong naturalistic
drug effects in discrete regions of tissue in vivo. We present here
the synthesis and characterization of a novel α2 adrenergic
agonist photolabel based on the imidazole medetomidine called azi-medetomidine. Azi-medetomidine shares protein association
characteristics with its parent compound in experimental model systems
and by molecular dynamics simulation of interactions with the α2A adrenergic receptor. Azi-medetomidine acts as an agonist
at α2A adrenergic receptors, and produces hypnosis
in Xenopus laevis tadpoles. Azi-medetomidine competes
with the α2 agonist clonidine at α2A adrenergic receptors, which is potentiated by photolabeling, and
azi-medetomidine labels moieties on the α2A adrenergic
receptor as determined by mass spectrometry in a manner consistent
with a simulated model. This novel α2 adrenergic
agonist photolabel can serve as a powerful tool for in vitro and in
vivo investigations of adrenergic signaling.